Xeris Biopharma Holdings, Inc. XERS
- Market cap
- $1.6B
- P/E
- 0.0×
Follow XERS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | 15.01 | 6.81 | 1.42 | 1.77 | 1.14 | 0.97 | 1.69 | 3.14 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | 27.98 | 18.88 | 7.24 | 7.94 | 3.10 | 3.07 | 3.87 | 10.08 |
High Price
|
|||
| — | 55 | 90 | 202 | 180 | 294 | 355 | 377 | 394 | 435 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Revenue/Emp
|
|||
| 1 | 2 | 2 | 3 | 20 | 50 | 110 | 164 | 203 | 292 |
Revenue
|
|||
| 99.26% | 99.74% | 100.00% | 41.11% | 54.35% | 73.14% | 79.47% | 82.52% | 81.86% | 85.41% |
Gross Margin
|
|||
| (13) | (27) | (60) | (126) | (91) | (123) | (96) | (64) | (57) | 1 |
EBT
|
|||
| (1,228.74%) | (1,706.56%) | (2,479.57%) | (4,630.35%) | (446.54%) | (247.48%) | (87.15%) | (38.74%) | (28.12%) | 0.19% |
EBT Margin
|
|||
| (13) | (27) | (60) | (126) | (91) | (123) | (95) | (62) | (55) | 1 |
Net Income
|
|||
| 0 | 0 | 1 | 2 | 2 | 3 | 14 | 15 | 16 | 16 |
Depreciation
|
|||
| 0.58 | 0.77 | 0.20 | 0.10 | 0.48 | 0.63 | 0.81 | 1.19 | 1.38 | 1.82 |
Revenue/Sh
|
|||
| (7.17) | (13.09) | (4.99) | (4.81) | (2.14) | (1.55) | (0.70) | (0.45) | (0.37) | 0.00 |
Earnings/Sh
|
|||
| (8.73) | (12.16) | (4.67) | (4.00) | (1.89) | (1.21) | (0.76) | (0.34) | (0.25) | 0.18 |
Cash Flow/Sh
|
|||
| (0.02) | (0.35) | (0.13) | (0.04) | (0.01) | (0.01) | 0.00 | (0.02) | (0.01) | 0.00 |
Capex/Sh
|
|||
| (8.75) | (12.51) | (4.80) | (4.04) | (1.90) | (1.22) | (0.76) | (0.36) | (0.26) | 0.17 |
Free CF/Sh
|
|||
| 16.81 | 19.75 | 6.26 | 0.55 | 0.79 | 1.21 | 0.33 | (0.05) | (0.20) | 0.09 |
Book Value/Sh
|
|||
| 2 | 2 | 12 | 26 | 43 | 79 | 136 | 138 | 147 | 160 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,065.79 |
PE Ratio
|
|||
| 0.00 | 0.00 | 84.52 | 67.63 | 10.27 | 4.67 | 1.38 | 1.91 | 2.45 | 4.32 |
PS Ratio
|
|||
| 0.00 | 0.00 | 2.72 | 12.75 | 6.21 | 2.43 | 3.36 | 0.00 | 0.00 | 92.00 |
PB Ratio
|
|||
| 0.00 | 0.00 | 51.19 | 62.39 | 8.13 | 4.44 | 1.98 | 2.64 | 3.24 | 4.73 |
EV/Sales
|
|||
| (0.35) | (0.35) | (2.15) | (1.61) | (2.05) | (2.28) | (2.11) | (8.79) | (17.39) | 49.43 |
EV/FCF
|
|||
| (16) | (25) | (56) | (104) | (81) | (96) | (103) | (47) | (37) | 29 |
Op' Cash Flow
|
|||
| 0 | (1) | (2) | (1) | 0 | (1) | (1) | (2) | (1) | (1) |
Capex
|
|||
| (16) | (25) | (58) | (105) | (81) | (97) | (103) | (49) | (38) | 28 |
FCF
|
|||
| 31 | 39 | 108 | 60 | 124 | 64 | 113 | 61 | 67 | 131 |
Working Cap'
|
|||
| — | — | 32 | 58 | 87 | 88 | 189 | 191 | 232 | 220 |
Total Debt
|
|||
| (32) | (42) | (81) | (17) | (47) | (14) | 67 | 118 | 160 | 109 |
Net Debt
|
|||
| 31 | 40 | 75 | 14 | 34 | 95 | 45 | (7) | (30) | 14 |
Sh' Equity
|
|||
| (33.64%) | (67.63%) | (72.81%) | (109.67%) | (67.98%) | (52.95%) | (29.18%) | (18.66%) | (16.99%) | 0.16% |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (89.00%) | (45.78%) | (24.63%) | (16.07%) | 12.65% |
ROIC
|
|||
| 29.43% | 59.16% | (683.66%) | (279.56%) | (378.20%) | (190.28%) | (134.83%) | (324.20%) | 301.32% | (6.96%) |
ROE
|
|||
Xeris Biopharma Holdings, Inc. peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ANIP ANI Pharmaceuticals, Inc. | $1.7B | 15.3× | Compare |
| ETON Eton Pharmaceuticals, Inc. | $1.7B | 123× | Compare |
| PAHC Phibro Animal Health Corporation | $1.4B | 14.0× | Compare |
| PRGO Perrigo Company plc | $2.1B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| HROW Harrow, Inc. | $1.2B | 0.0× | Compare |
| PBH Prestige Consumer Healthcare Inc. | $2.2B | 13.0× | Compare |
| CRON Cronos Group Inc. | $1.2B | 16.7× | Compare |
| BCRX BioCryst Pharmaceuticals, Inc. | $2.2B | 0.0× | Compare |
Xeris Biopharma Holdings, Inc. (XERS) key facts
- Xeris Biopharma Holdings, Inc. (XERS) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- As of September 25, 2026, XERS traded at $9.10, a market capitalization of $1.6 billion.
- Return on equity was −6.96% and debt-to-equity -25.95.
Xeris Biopharma Holdings, Inc. (XERS) Latest News
9 Sep
Xeris Biopharma Holdings is hosting a webinar detailing its development program for XP-8121, an investigational once-weekly subcutaneous levothyroxine for hypothyroidism. XP-8121 program progress indicates pipeline development in hypothyroidism treatment with moderate potential to shape future performance.
15 Aug
Xeris Biopharma Holdings tightened its 2026 revenue guidance and advanced XP-8121, driving an 8.4% stock increase. Tightening 2026 revenue guidance and advancing XP-8121 signals pipeline progress and financial outlook updates likely to moderately influence Xeris Biopharma's trajectory.
14 Aug
Xeris Biopharma Holdings reported record Q2 revenue. Record quarterly revenue improves reported financials but leaves core trajectory and competitive position unchanged.
13 Aug
Xeris (XERS) released the transcript of its Q2 2026 earnings call covering financial results, operations, and outlook. Quarterly earnings calls deliver performance updates that moderately influence near-term sentiment and positioning without guaranteeing major trajectory shifts.
7 Aug
Xeris Biopharma Holdings reported Q2 earnings call highlights covering financial results, operational updates and forward-looking guidance for the company. Q2 earnings highlights deliver updated financials and strategy notes that can shift near-term sentiment but rarely redefine long-term trajectory.
6 Aug
Xeris Biopharma Holdings Inc posted record revenue in its Q2 2026 earnings call. Record revenue signals stronger financial results that can lift valuation and investor outlook.
Xeris Biopharma (XERS) Q2 earnings results are compared to Wall Street estimates with analysis of key financial metrics. Q2 earnings versus estimates deliver moderate insight into financial performance and can shift near-term investor sentiment.
Xeris Biopharma Holdings, Inc. reported its second quarter 2026 financial results. Quarterly financial results directly inform company performance and investor sentiment.
30 Jun
Extended Keveyis exclusivity may position Xeris Biopharma Holdings for long-term XERS stock growth. Extended Keveyis exclusivity strengthens Xeris revenue protection and competitive position.
11 Jun
Xeris Biopharma received notice of allowance from the U.S. Patent and Trademark Office for a new patent covering KEVEYIS®. New patent strengthens IP protection around existing KEVEYIS® product and may support competitive positioning.
15 May
Xeris Biopharma Holdings (NASDAQ:XERS) delivered high-quality earnings that should please shareholders. High-quality earnings signal strong financial health, moderately boosting investor sentiment and stock trajectory.
9 May
Xeris Biopharma Holdings, Inc. (XERS) reported a surprise profit, exceeding analyst expectations. Surprise profit beat signals improved financial health, likely driving significant positive shifts in investor sentiment and stock trajectory.
Xeris Biopharma Holdings, Inc. (XERS) released Q1 earnings call highlights detailing financial results, revenue growth, pipeline updates, and forward guidance. Q1 earnings highlights provide insights into financial performance and strategic outlook with moderate influence on market sentiment and trajectory.
8 May
Xeris Biopharma Holdings (XERS) stock rose 8.2% after reporting a swing to Q1 profitability, driven by key operational changes. Swing to Q1 profitability signals improved financial health and positively shifts investor sentiment and stock performance.
Xeris Biopharma Holdings, Inc. (XERS) released Q1 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Q1 2026 earnings call summary covers financial performance and strategic updates with moderate influence on stock sentiment and trajectory.
7 May
Xeris Biopharma Holdings (XERS) Q1 2026 earnings call transcript details quarterly financial results, revenue growth, pipeline progress, strategic partnerships, and updated guidance. Quarterly earnings disclosure with financials, pipeline updates, and guidance significantly shapes investor sentiment and company trajectory.
Xeris Biopharma (XERS) Q1 earnings key metrics compared to analyst estimates, highlighting performance in revenue, EPS, and other financial indicators. Q1 earnings metrics versus estimates significantly influence stock price, investor sentiment, and future valuation trajectory.
Xeris Biopharma Holdings, Inc. (XERS) reported first quarter 2026 financial results. Quarterly financial results disclosure signals revenue, profitability, and pipeline progress, significantly influencing stock performance and investor sentiment.
13 Apr
Xeris Biopharma Holdings, Inc. (XERS) delivered record Q4 results, issued robust 2026 guidance, and faces a Recorlev patent suit, raising questions on whether these factors bolster the bull case. Record Q4 results and strong 2026 guidance indicate significant financial momentum and growth prospects for XERS, outweighing patent suit risks.
3 Mar
Xeris Biopharma Holdings, Inc. (XERS) achieves new profitability while facing patent battles over Recorlev, balancing financial gains against competitive threats to its key drug. New profitability strengthens financial performance, but Recorlev patent disputes introduce moderate competitive and revenue risks.
2 Mar
Xeris Biopharma Holdings Inc (XERS) reported record revenue growth in Q4 2025 earnings call highlights. Record revenue growth represents a major financial milestone poised to significantly enhance XERS's market performance and investor sentiment.
Xeris Biopharma Holdings, Inc. (XERS) released Q4 2025 earnings call summary detailing quarterly financial results, operational updates, and forward guidance. Q4 earnings call summary delivers key financial metrics and strategic insights capable of significantly shifting investor sentiment and company trajectory.
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 earnings call transcript details financial results, revenue growth, pipeline progress, and 2026 guidance. Q4 2025 earnings transcript discloses financial performance, product updates, and outlook that could significantly sway investor sentiment and stock trajectory.
Xeris Biopharma Holdings, Inc. (XERS) Q4 earnings call highlights financial results, operational updates, pipeline progress, and strategic outlook for the biopharma company. Q4 earnings highlights directly affect financial performance, revenue guidance, and investor sentiment on future growth.
Xeris Biopharma Holdings, Inc. (XERS) reported record performance for the fourth quarter and full year 2025, and provided full year 2026 guidance. Record financial performance and forward guidance indicate strong growth momentum and positive investor sentiment for future trajectory.
Xeris Biopharma Holdings, Inc. (XERS) reported Q4 earnings, analyzing key metrics for insights into financial performance and future prospects. Q4 earnings reports moderately affect financial performance perceptions and short-term market sentiment.
Xeris Biopharma Holdings, Inc. (XERS) Q4 earnings and revenues exceeded analyst estimates. Surpassing Q4 earnings and revenue estimates positively impacts financial performance and investor sentiment.
Xeris Biopharma Holdings, Inc. (XERS) released Q4 earnings snapshot detailing key financial results for the quarter. Q4 earnings directly influence financial performance and short-term market sentiment without fundamentally altering long-term trajectory.
1 Mar
Xeris Biopharma Holdings (XERS) faces valuation scrutiny amid legal fight to protect Recorlev drug exclusivity against challenges threatening market position. Efforts to defend Recorlev exclusivity represent major regulatory risk that could significantly alter revenue trajectory and investor sentiment.
26 Feb
Xeris Biopharma Holdings, Inc. (XERS) subsidiaries filed a patent infringement lawsuit over Recorlev® to protect intellectual property rights. Defending Recorlev® patents via lawsuit secures market exclusivity and competitive edge, significantly impacting revenue trajectory.